Catalysts / SLS
Upcoming FDA decisions and readouts we track for SELLAS Life Sciences Group, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for SELLAS Life Sciences Group (SLS, listed on Nasdaq). It concerns SLS009 (tambiciclib) (Newly diagnosed first-line acute myeloid leukaemia).
First on the list: the Phase 2 readout for SLS009 (tambiciclib) (Newly diagnosed first-line acute myeloid leukaemia), guided by the company to Q4 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| SELLAS Life Sciences Group SLS · Nasdaq | SLS009 (tambiciclib) | Newly diagnosed first-line acute myeloid leukaemia | Q4 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList